Konstantin Linnik Presents at CHI’s 4th Annual Immuno-Oncology SummitPrint PDF
Konstantin Linnik, Ph.D., a partner in Nutter’s Intellectual Property Department and a member of the firm’s Life Sciences practice group, will present on the “Best Practices for Organizations and Academic Labs Entering the Cancer Immunotherapy Space” panel at Cambridge Healthtech Institute’s (CHI) Fourth Annual Immuno-Oncology Summit on August 31. Konstanin’s panel is part of the “Rational Combination Cancer Immunotherapy” conference section, which explores the clinical experience and key considerations for different immunotherapy combination strategies and considers the most essential best practices for organizations wanting to successfully link their therapeutic programs to approved checkpoint inhibitors. The conference provides a focused look at how researchers are applying new science and technology in the development of the next generation of effective and safe immunotherapies, and includes topics ranging from early discovery through clinical development as well as emerging areas such as oncolytic virotherapy.
Konstantin’s panel will focus on the vast scientific potential of immunotherapy combinations and how the clinical successes in this space have attracted significant numbers of large and small players to the field. Panelists will dissect the most important scientific and strategic considerations for those wanting to participate in these collaborations and offer audience members the opportunity for focused feedback from experts in business, regulatory, scientific, healthcare and dealmaking functions.